-
REAL WORLD USE AND OUTCOMES OF OLAPARIB IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: A RETROSPECTIVE STUDY FROM ITALIAN ADMINISTRATIVE DATABASES
Aug 11, 2026, 17:15 PM -
ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN CHILE USING REAL WORLD DATA (RWD) FROM THE PERSPECTIVE OF THE PRIVATE HEALTH SYSTEM (ISAPRES)
Aug 11, 2026, 17:15 PM -
DUPILUMAB VERSUS OMALIZUMAB IMPROVES CLINICAL OUTCOMES IN PATIENTS WITH SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, COEXISTING ASTHMA, AND ANOSMIA IN THE PHASE 4 EVEREST STUDY
Aug 11, 2026, 17:15 PM -
DETERMINATION OF THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE EXPLORING ANCHOR-BASED METHODS: CASE STUDY IN MULTIPLE SCLEROSIS OF THE MSAS SCALE
Aug 11, 2026, 17:15 PM -
TKIS IN THE FIRST LINE OF CHRONIC MYELOID LEUKEMIA. COST OF ADVERSE EVENTS IN SPAIN
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF A STRUCTURED LIFESTYLE INTERVENTION FOR TYPE 2 DIABETES PREVENTION IN PRIMARY CARE IN SPAIN
Aug 11, 2026, 17:15 PM -
REAL-WORLD CLINICAL OUTCOMES AND CORRELATION OF RECURRENCE FREE SURVIVAL (RFS) AND DISTANT METASTASIS FREE SURVIVAL (DMFS) TO OVERALL SURVIVAL (OS) IN RESECTED STAGE IIB/C CUTANEOUS MELANOMA
Aug 11, 2026, 17:15 PM -
ESTIMATING THE PUBLIC HEALTH AND ECONOMIC BENEFIT ASSOCIATED WITH THE IMPLEMENTATION OF AN ADULT RSV NATIONAL IMMUNISATION PROGRAMME IN ENGLAND
Aug 11, 2026, 17:15 PM -
IMPACT OF VIRTUAL MATERNITY PROGRAM ENGAGEMENT ON NEONATAL OUTCOMES AND COSTS IN A COMMERCIAL POPULATION
Aug 11, 2026, 17:15 PM -
ESTIMATING THE PUBLIC HEALTH IMPACT ATTRIBUTABLE TO LATE COVID-19 VACCINE STRAIN SELECTION IN THE UNITED STATES: AN EXPLORATORY MODELING ANALYSIS
Aug 11, 2026, 17:15 PM -
EARLY LUNG CANCER DETECTION USING ARTIFICIAL INTELLIGENCE ON CHEST X-RAYS: THE BUDGET IMPACT OF IMPLEMENTING INCIDENTAL PULMONARY NODULE DETECTION IN TURKIYE
Aug 11, 2026, 17:15 PM -
DISCRETE EVENT SIMULATION OF CHRONIC KIDNEY DISEASE IN THE USA
Aug 11, 2026, 17:15 PM -
PHARMACOVIGILANCE STUDY OF FARICIMAB, AFLIBERCEPT, AND RANIBIZUMAB IN NAMD AND DME: FAERS-BASED INSIGHTS ON OCULAR ADVERSE EVENTS
Aug 11, 2026, 17:15 PM -
NETWORK META-ANALYSIS (NMA) OF NEOADJUVANT-ADJUVANT TREATMENT PATHWAYS IN HER2+ EARLY BREAST CANCER (EBC) TO INFORM COST-EFFECTIVENESS
Aug 11, 2026, 17:15 PM -
TRUST-MM | TRANSLATING US REAL-WORLD DATA TO UK CLINICAL PRACTICE: TREATMENT PATTERNS AND OUTCOMES IN FIRST LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF FINERENONE FOR CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN KOREA: RESULTS OF THE FINE-CKD MODEL
Aug 11, 2026, 17:15 PM -
A COST-UTILITY ANALYSIS OF INITIATING PATIENTS ON PERITONEAL DIALYSIS VERSUS IN-CENTRE HAEMODIALYSIS IN THE UNITED KINGDOM
Aug 11, 2026, 17:15 PM -
IMPROVING EFFICIENCY IN REAL-WORLD EVIDENCE SLRS WITHOUT COMPROMISING VALIDITY: IMPLICATIONS FOR BIOPHARMA
Aug 11, 2026, 17:15 PM -
A DEDUCTIVE LARGE LANGUAGE MODEL (LLM) WORKFLOW FOR MULTI-TOPIC EVIDENCE LANDSCAPE MAPPING AT SCALE
Aug 11, 2026, 17:15 PM -
PRACTICAL CHALLENGES IN THE IMPLEMENTATION OF ML-NMR FOR RATE OUTCOMES: LESSONS FROM A RECENT EUROPEAN HTA SUBMISSION
Aug 11, 2026, 17:15 PM
